plateau_notes

TL2 Regular · Wellington, NZ

Plateaus, real and imagined. I have a spreadsheet and a healthy scepticism about week-to-week readings.

Joined 12 July 2025 · last posted 4d

82 posts, newest first. Showing up to 150.

Aggregate verification data across the directory, with caveats Replied, post #68 · Sourcing › Independent verification · 24 Jul 2026 · 21 likes I had written a reply contradicting post #66 and deleted it. Here is what survived. Nobody has said the unglamorous part of aggregate verification data yet, so: most of…
Here for the analytics and not much else Replied, post #76 · Lounge › Introductions · 23 Jul 2026 · 0 likes Welcome. If you have an analytical background you will find the analytics subcategories the easiest place to be useful quickly — the recurring gap here is people who…
[2026 update] Interpreting a result that disagrees with the supplier's certificate Replied, post #105 · Sourcing › Independent verification · 19 Jul 2026 · 0 likes I would put moderate confidence on the mainstream reading of Interpreting a result and no more. That is not scepticism for its own sake; it is where the sourcing…
Journal club: SUSTAIN 6 and its retinopathy signal Replied, post #73 · Evidence › Journal club · 16 Jul 2026 · 0 likes My position on SUSTAIN 6 is current rather than settled. I have revised it once already and I expect to again, so treat it accordingly.
Coming back to: Specificity, linearity, accuracy, precision, range, robustness — with… Replied, post #88 · Analytics › Method validation · 13 Jul 2026 · 17 likes This settles it for me, at least until somebody posts a reason it should not.
Why we ask for units every single time, with three examples of what goes wrong Replied, post #123 · Start Here › How to Ask · 13 Jul 2026 · 0 likes Worth separating two things that post #120 runs together. Nobody minds being asked to explain a term. The people who use them most are the quickest to define them, and…
What a reversed-phase purity number actually is Replied, post #38 · Analytics › HPLC & UHPLC · 9 Jul 2026 · 3 likes Where I part company with post #36, and it is a narrow parting. Peak purity: a diode-array detector records a spectrum at every time point. If a peak contains two…
Publication patterns in the BPC-157 literature, examined Replied, post #31 · Compounds › Repair & healing peptides · 9 Jul 2026 · 4 likes BPC-157's published evidence is overwhelmingly preclinical and mostly rodent. That is not a dismissal — it is the state of the literature, and any discussion that…
Aggregate verification data across the directory, with caveats Replied, post #28 · Sourcing › Independent verification · 4 Jul 2026 · 20 likes The most useful thing anyone has posted about aggregate verification data in this category was a table of what had been measured and by whom. That is what I would want…
Reading a rodent study on a secretagogue without over-extrapolating — the long version Replied, post #8 · Compounds › Secretagogues & GH axis · 24 Jun 2026 · 7 likes Narrowing post #7, because the general version has more than one answer. My position on Reading a rodent study is current rather than settled. I have revised it once…
Request: a per-category review queue Replied, post #56 · Meta › Feature requests · 24 Jun 2026 · 0 likes Answering the question post #52 raises rather than the one it answers. That would also make review dates far more meaningful. A document cited by forty topics and a…
What consumer-accessible tests can and cannot determine — a second dataset Replied, post #20 · Analytics › Home & field testing · 22 Jun 2026 · 15 likes Good question, well framed, and I would like to see it answered properly.
The anatomy of a question that gets answered within an hour Replied, post #85 · Start Here › How to Ask · 21 Jun 2026 · 17 likes Clear enough that I do not think I have a follow-up, which is unusual.
Alcohol: what is documented and what is folklore Replied, post #64 · Practice › Interactions · 18 Jun 2026 · 2 likes Where I part company with post #61, and it is a narrow parting. SGLT2 inhibitors: frequently co-administered and relevant to renal and cardiovascular discussion, not to…
Comparing prices across jurisdictions without misleading yourself Replied, post #70 · Access › Pricing · 12 Jun 2026 · 14 likes Post #68 is right about the mechanism and I think understates the practical bit. Biosimilars and future generics: as patents expire, biosimilar and generic versions…
Personal import allowances, compared — a second dataset Replied, post #128 · Access › International · 22 May 2026 · 16 likes This settles it for me, at least until somebody posts a reason it should not.
Amylin receptor signalling and satiety — what changed since Replied, post #79 · Pharmacology › Receptor biology · 14 May 2026 · 15 likes Coming back to post #77, because the follow-up matters more than the original answer. Biased agonism — where different ligands at the same receptor favour different…
Revisiting: PCOS and metabolic overlap: what is and is not studied Replied, post #26 · Clinical › Comorbidities · 10 May 2026 · 13 likes Age at the extremes of the studied range is an extrapolation in both directions, and the trials generally studied a narrower band than the discussion assumes.
[2026 update] A vial that will not fully dissolve: what to check and in what order Replied, post #27 · Practice › Reconstitution · 27 Apr 2026 · 12 likes Swirling until fully clear before drawing is worth the extra minute. A partially dissolved preparation is not uniform and the first dose out of it is not the same as…
Run-in periods and the population they select Replied, post #106 · Evidence › Trials · 26 Apr 2026 · 12 likes Nothing in a trial report is medical advice about an individual, and the gap between a population estimate and a person is exactly where clinical judgement lives.…
Converting between mg/mL and units per dose, both directions — the long version Replied, post #73 · Practice › Reconstitution · 22 Apr 2026 · 12 likes I came in to disagree and I am leaving without a disagreement.
The best-written scientific paper you have read Replied, post #12 · Lounge › Off topic · 20 Apr 2026 · 0 likes Off-topic but genuinely curious: how many people here came in through the analytics side rather than the practical side? The two groups seem to read completely…
Adducts: sodium, potassium, and the peak you did not expect — does this still hold? Replied, post #106 · Analytics › Mass spectrometry · 13 Apr 2026 · 9 likes The failure mode on Adducts is boring rather than dramatic. It is almost always the step everyone assumes was done correctly because it is too simple to get wrong.
Spike-and-recover accuracy for a peptide assay Replied, post #94 · Analytics › Method validation · 10 Apr 2026 · 12 likes The arithmetic in post #93 is right; the assumption feeding it is the part to check. Before the thread moves on from spike-and-recover accuracy — what is the sample…
Bug report: the reconstitution calculator and a rounding edge case Started this topic · Data & Tools › Calculators · 30 Mar 2026 · 2 likes Bug report: the reconstitution calculator and a rounding edge case — setting out what I have, and where I think it stops being reliable. Posting the calculation with…
What "marked as solution" means and who gets to mark it Started this topic · Start Here › Welcome · 26 Mar 2026 · 0 likes Asking directly, because I could not find a straight answer: What "marked as solution" means and who gets to mark it Question in the title. Context below, and I have…
Half-life, steady state, and accumulation worked through — a second dataset Replied, post #115 · Pharmacology › Pharmacokinetics · 25 Mar 2026 · 0 likes Half-life: semaglutide ≈ 165–184 hours (about a week). Tirzepatide ≈ 5 days. Liraglutide ≈ 13 hours. The half-life determines how much accumulation happens at steady…
Type 2 diabetes and the largest part of the evidence base Replied, post #37 · Clinical › Comorbidities · 20 Mar 2026 · 25 likes Coming back to post #35, because the follow-up matters more than the original answer. Where two conditions pull in opposite directions, that is a clinical judgement…
Reading an interaction checker output critically Replied, post #151 · Practice › Interactions · 20 Mar 2026 · 0 likes Adding the measurement that post #150 says would settle it. SGLT2 inhibitors: frequently co-administered and relevant to renal and cardiovascular discussion, not to…
Micro-titration: a disputed topic, argued properly — one year on Replied, post #15 · Practice › Dosing & titration · 19 Mar 2026 · 1 like No disagreement from me. Posting only so the question does not look ignored.
How Janoshik, Medutest, PeptideMeter and VendorInvestigate differ — a second dataset Replied, post #31 · Sourcing › Independent verification · 11 Mar 2026 · 2 likes Post #28 is the version of this I will quote in future. One addition. The record shows what was measured. Everything beyond that is inference and this site tries to…
[2026 update] Thyroid function tests during substantial weight change Replied, post #12 · Clinical › Bloodwork · 10 Mar 2026 · 20 likes Rate of change is frequently more informative than absolute value, and it is only available if the earlier results were kept.
Reconstitution volumes that produce round numbers, tabulated Replied, post #59 · Practice › Reconstitution · 5 Mar 2026 · 0 likes Worked example, since the arithmetic is the whole question. Five milligrams into one millilitre is 5 mg/mL. A 0.25 mg dose is 0.05 mL, which is five units on a U-100…
A site rotation scheme that is easy enough to actually follow Replied, post #14 · Practice › Administration · 4 Mar 2026 · 0 likes The version of site rotation scheme that circulates here is a simplification of a simplification. It is not wrong, but it has lost the conditions under which it holds,…
Second pass at: Where impurities in solid-phase peptide synthesis come from Replied, post #25 · Analytics › Impurities & related substances · 23 Feb 2026 · 6 likes The practical version of impurities in solid-phase peptide synthesis is three sentences long. The rigorous version is three pages and reaches the same conclusion with…
Publication bias detection and its low power — does this still hold? Replied, post #10 · Evidence › Meta-analyses · 3 Feb 2026 · 5 likes Narrowing post #7, because the general version has more than one answer. Small methodological point on Publication bias detection: repeating a measurement is cheap and…
Search filters: what is missing Replied, post #17 · Meta › Site feedback · 12 Jan 2026 · 13 likes One caution on search filters: everything above assumes the underlying documentation is what it claims to be. That assumption is doing real work and is rarely stated.
Follow-up: A supplier that answers analytical questions with restated claims Replied, post #43 · Sourcing › Red flags · 9 Jan 2026 · 27 likes Post #41 describes the usual case. This is about the unusual one. Evasion when asked: if a supplier does not clarify when asked specifically for method details,…
Vomiting: when it is expected and when it is a reason to stop Replied, post #73 · Practice › Side effects · 29 Dec 2025 · 16 likes The relationship between symptom burden and outcome is not what people assume. Feeling worse is not evidence of a larger effect and feeling nothing is not evidence of…
Can a home kit substitute for a laboratory report? A careful no Replied, post #85 · Analytics › Home & field testing · 22 Dec 2025 · 0 likes A control sample of known material run alongside is what turns a home test from an impression into a comparison. Without one you are calibrating against memory. That…
Sequence verification for an obscure compound: how it is done — what changed since Replied, post #21 · Compounds › Other compounds · 23 Nov 2025 · 6 likes I will take the caveat as seriously as the claim, which is the point of putting it there.
Robustness: the parameters worth deliberately varying Replied, post #7 · Analytics › Method validation · 18 Nov 2025 · 1 like No disagreement from me. Posting only so the question does not look ignored.
Pooling trials with different estimands — what changed since Replied, post #52 · Evidence › Meta-analyses · 17 Nov 2025 · 0 likes This is the answer, and the reason it is the answer is the more useful part.
Coming back to: The SOUL trial and oral semaglutide cardiovascular outcomes Replied, post #50 · Compounds › Oral incretins · 17 Oct 2025 · 13 likes Building on post #48 rather than restating it. Research-use-only oral material is not a licensed tablet and there is no reason to assume it carries a functioning…
Sleep tracking data and its considerable limitations Replied, post #6 · Wellbeing › Sleep · 15 Oct 2025 · 7 likes Agreed on all of that, and I have nothing to add to it.
Cagrilintide's dosing interval and the pharmacokinetics behind it Replied, post #34 · Compounds › Cagrilintide & amylin analogues · 2 Oct 2025 · 3 likes The monoisotopic mass sits near 3749.9 Da, and the same caveat applies as everywhere else: a mass consistent with the proposed structure is a necessary condition and…
A parcel that arrived warm: a decision process, not a verdict Replied, post #29 · Practice › Storage & stability · 8 Sep 2025 · 1 like Thank you — that answers what I came here to find out.
Second pass at: Why this subcategory is stricter about sourcing than most Replied, post #123 · Compounds › Secretagogues & GH axis · 1 Sep 2025 · 11 likes Reconstitution volumes in this family are often small enough that dead volume in the syringe is a meaningful fraction of the dose. A fixed-needle insulin syringe is…
How to read a forest plot, properly, from scratch Replied, post #22 · Evidence › Trials · 1 Sep 2025 · 0 likes Sensible. I would want the same detail before I acted on it either.
[2026 update] Journal club: is percentage weight change the right endpoint? Replied, post #102 · Evidence › Journal club · 24 Aug 2025 · 0 likes The most common failure mode is spending fifty minutes on the effect size and ten on the population. Reversing that ratio would improve most sessions.
Follow-up: Why the titration planner refuses to produce a schedule below a floor Replied, post #91 · Data & Tools › Calculators · 22 Aug 2025 · 0 likes Having read the whole titration planner refuses thread before replying: the question in the first post has not actually been answered yet, and three of us have answered…
Second pass at: The mass-error checker and its intended scope Replied, post #4 · Data & Tools › Calculators · 21 Aug 2025 · 0 likes No notes. Posting so the count is not one.
Why oral semaglutide needs an absorption enhancer at all Replied, post #17 · Compounds › Oral incretins · 9 Jul 2025 · 0 likes Before the thread moves on from oral semaglutide — what is the sample size behind the claim? I am not being difficult; I have seen the same figure quoted from an n of…
Journal club: the CagriSema phase 2 combination paper — a second dataset Replied, post #62 · Evidence › Journal club · 1 Jul 2025 · 0 likes Post #59 is right about the mechanism and I think understates the practical bit. Second-hand on CagriSema phase 2 combination paper, so weight it accordingly — someone…
Hepatic steatosis: what the MASH trial evidence supports Replied, post #58 · Clinical › Comorbidities · 6 Jun 2025 · 0 likes Where I part company with post #54, and it is a narrow parting. Hepatic steatosis is one of those subjects where the general answer and the answer for a specific case…
Preparing for an appointment: one page, three questions Replied, post #20 · Clinical › Prescriber conversations · 26 May 2025 · 0 likes Written summaries after an appointment are available in many systems and are worth asking for, because recollection of a consultation is unreliable. I am describing…
How Janoshik, Medutest, PeptideMeter and VendorInvestigate differ Replied, post #16 · Sourcing › Independent verification · 26 Apr 2025 · 0 likes Everything in post #12 holds. The case it does not cover is the one I have. It does not extend to lots nobody has seen, it is not a recommendation, and it says nothing…
Coming back to: What published stability data actually covers, and what it does not Replied, post #20 · Practice › Storage & stability · 12 Apr 2025 · 31 likes Saving this. It is the version I will quote when the question comes round again.
Carryover and the ghost peak from last week's standard Replied, post #16 · Analytics › HPLC & UHPLC · 2 Apr 2025 · 16 likes Gradient slope is the single biggest driver of apparent purity differences. A shallower gradient over a longer run resolves more impurities and gives a higher purity…
Splitting a vial for two laboratories: how to do it without ruining both Replied, post #12 · Sourcing › Independent verification · 1 Apr 2025 · 0 likes PeptideMeter: purity analysis plus structured, dated supplier verification records. Produces both individual analytical results and verification records assessed over…
Retatrutide dose escalation in the published trials Replied, post #70 · Compounds › Retatrutide · 31 Mar 2025 · 16 likes Answering the question post #68 raises rather than the one it answers. Comparisons with tirzepatide are being made across trials rather than within one. Different…
What the published dose-response for semaglutide actually looks like above 2.4 mg — a… Replied, post #118 · Compounds › Semaglutide · 26 Mar 2025 · 23 likes Post #116 describes the usual case. This is about the unusual one. Having read the whole published dose-response for semaglutide thread before replying: the question in…
Journal club: SURMOUNT-OSA and a hard endpoint in a soft field Replied, post #42 · Evidence › Journal club · 14 Mar 2025 · 0 likes The failure mode on SURMOUNT-OSA is boring rather than dramatic. It is almost always the step everyone assumes was done correctly because it is too simple to get wrong.
Why a pen's dose steps are fixed and what that costs you — one year on Replied, post #4 · Devices › Pens & autoinjectors · 6 Mar 2025 · 0 likes The residual left in a cartridge at the end is deliberate overfill and is not a dose you are entitled to extract. Attempting to recover it is where accuracy goes.
Pharmaceutical compounding rules, summarised from primary sources Replied, post #100 · Sourcing › Regulatory · 4 Mar 2025 · 0 likes That matches what I have seen, for whatever a single anecdote is worth.
An orphaned page with no inbound links Replied, post #12 · Meta › Wiki maintenance · 26 Feb 2025 · 0 likes The thing about orphaned page that took me longest to accept is that a plausible mechanism is not evidence of an effect. It is a reason to look, not a result.
What the published dose-response for semaglutide actually looks like above 2.4 mg — a… Replied, post #57 · Compounds › Semaglutide · 9 Feb 2025 · 12 likes I had written a reply contradicting post #55 and deleted it. Here is what survived. Where the published dose-response for semaglutide reasoning breaks down for me is…
Second pass at: Gauge and length selection for subcutaneous injection Replied, post #26 · Devices › Syringes & needles · 3 Feb 2025 · 20 likes Everything in post #24 holds. The case it does not cover is the one I have. The version of Gauge and length selection that circulates here is a simplification of a…
Second pass at: Certificates issued by the seller versus by a laboratory Replied, post #27 · Analytics › COA interpretation · 19 Jan 2025 · 0 likes The distinction between release testing and characterisation is one industrial documents make and retail ones usually do not. It is the difference between "we tested…
[2026 update] Lipid changes during rapid weight loss: the expected trajectory Replied, post #19 · Clinical › Bloodwork · 15 Jan 2025 · 0 likes The arithmetic in post #18 is right; the assumption feeding it is the part to check. Glycaemic markers integrate over different periods. A point glucose and a…
Follow-up: Individual participant data versus aggregate data Replied, post #76 · Evidence › Meta-analyses · 11 Jan 2025 · 0 likes Funnel plots: a plot of study effect size versus sample size that helps detect publication bias. If small studies are missing on the negative side, the funnel is…
Oral semaglutide bioavailability and its variability between people — a second dataset Replied, post #105 · Compounds › Oral incretins · 28 Dec 2024 · 7 likes Speaking only to Oral semaglutide bioavailability as I have actually seen it, rather than as it is usually described: the effect is real, it is smaller than the thread…
When "no data" is the complete and final answer Replied, post #51 · Compounds › Other compounds · 27 Dec 2024 · 14 likes Noted, and I have changed what I was going to do on the strength of it.
Second pass at: Choosing a concentration on purpose rather than by accident Replied, post #31 · Practice › Reconstitution · 30 Nov 2024 · 21 likes That matches what I have seen, for whatever a single anecdote is worth.
Reading a preclinical wound-healing model and its relevance to a human tendon Replied, post #146 · Compounds › Repair & healing peptides · 25 Nov 2024 · 0 likes Oral versus injected administration claims for BPC-157: the preclinical work studied injection. Oral claims are common in supplier marketing and poorly supported by…
Revisiting: Melanocortin agonists: mechanism and the documented adverse profile Replied, post #126 · Compounds › Other compounds · 19 Nov 2024 · 9 likes Solubility varies far more across this subcategory than within the incretins. A compound that needs a specific diluent or a specific pH is not being difficult; it has a…
Choosing which test to pay for, given a fixed budget — does this still hold? Replied, post #10 · Sourcing › Independent verification · 26 Oct 2024 · 6 likes A record with four results over sixteen months is a thin record rather than a bad one, and the honest description says which.
Irish differences from the UK position Replied, post #4 · Regional › UK & Ireland · 21 Sep 2024 · 15 likes Post #2 and I disagree about the size of the effect, not about the direction. Private prescribing arrangements differ in what they include, and the differences are more…
When to suspect the method rather than the sample Replied, post #13 · Analytics › Method validation · 17 Sep 2024 · 7 likes Range and working range are different things and a certificate rarely distinguishes them. The relevant one is the range over which this particular sample was measured.…
Semaglutide half-life: where the 165 to 184 hour figure comes from — what changed since Replied, post #4 · Compounds › Semaglutide · 29 Aug 2024 · 22 likes Semaglutide's structure is a modified backbone with a C18 diacid attached through a spacer. The acylation is the reason for the long half-life and it is also the reason…
Oral contraceptives and delayed emptying: what the data shows Replied, post #60 · Practice › Interactions · 17 Jul 2024 · 0 likes Grateful for the specificity. Vague answers to this question are what sent me looking.
Splitting a weekly dose in two: the pharmacokinetic argument against — the long version Replied, post #130 · Practice › Dosing & titration · 10 Jul 2024 · 0 likes Adding the measurement that post #127 says would settle it. The four-week step is a trial convention, not a pharmacological constant. It is roughly four half-lives for…